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New Directions in Library Design and Analysis 
 
Val Gillet 
 
Summary 
 
The high costs associated with high throughput screening (HTS) coupled with the limited 
coverage and bias of current screening collections is such that diversity analysis 
continues to be an important criterion in lead generation. Whereas early approaches to 
diversity analysis were based on traditional descriptors such as two dimensional 
fingerprints a recent emphasis has been on assessing scaffold coverage to ensure that a 
variety of different chemotypes are represented. Moreover, whether designing diverse or 
focussed libraries, it is widely recognised that designs should aim to achieve a balance in 
a number of different properties and multiobjective optimisation provides an effective 
way of achieving such designs. 
 
Introduction 
 
Although current HTS technologies permit up to one million compounds to be screened 
in a few weeks, the costs associated with running the screens and the need to replenish 
samples mean that this is not always desirable [1,2]. Furthermore, it may not always be 
possible to scale-up the assay to permit HTS. Thus, there is considerable pressure to 
minimise the number of compounds to be screened. Focussed screening involves the 
selection of a subset of compounds according to an existing structure-activity 
relationship, which could be derived from known active compounds or from a protein 
target site, depending on the available knowledge. Focussed screening is generally 
desirable; however, it is not always possible, for example, when little is known about the 
target. In such cases, screening sets are usually designed to be diverse and a sequential 
screening strategy may be followed. Sequential screening is an iterative process which 
starts with a small representative set of diverse compounds, the aim being to derive some 
structure-activity information during the first round of screening which is then be used to 
select more focussed sets in subsequent rounds of screening. Diversity analysis is also an 
important criterion when purchasing compounds from external vendors to augment an 
existing collection: despite a recent growth in corporate screening libraries, the chemical 
space they cover represents a tiny fraction of the space occupied by drug-like compounds 
(a typical corporate collection is in the region of 1 to 10 million compounds whereas even 
conservative estimates of drug-like chemical space are on the order of 1013 [3]). 
 
This review focuses on recent developments in library design with particular emphasis on 
scaffold diversity and combinatorial libraries.  
 
The rationale  
 
Diversity selection has its basis in the similar property principle which states that 
structurally similar compounds are likely to have similar properties. Thus compounds that 
are structurally similar to a known biologically active compound are likely to share the 
same activity. When considering diverse subsets, the aim is usually to maximise the 
coverage of structural space while minimising redundancy, i.e., the inclusion of 
compounds that are so similar that they share the same activity. The similar property 
principle forms the foundations of rational approaches to medicinal chemistry with 
numerous examples of its successful application in the literature, however, there are also 
many counter-examples where a small change in structure can result in the loss of 
activity, see for example [4]. 
 
A common approach to avoiding redundancy has been to use a similarity threshold, for 
example, a threshold of 0.85 similarity (using 2D descriptors and the Tanimoto 
coefficient) has been used to reject compounds for purchase [5]. This threshold was based 
on the observation that if two molecules are 85% similar and one is active, then the other 
has an 80% chance of also being active [6,7]. However, more recent work has shown a 
weaker relationship between structure and activity with, on average, only 30% of 
compounds within 0.85 similarity of an active compounds also being active [8]. This later 
finding has led to the reconsideration of appropriate thresholds to use when selecting 
diverse subsets of compounds. 
 
How is diversity measured? 
 
The components necessary to select a diverse subset of compounds include molecular 
descriptors and a subset selection method. Descriptors include physicochemical 
properties, topological indices, fingerprint-based descriptors derived from 2D connection 
tables and 3D conformations. Subset selection methods include dissimilarity-based 
compound selection which involves calculating pairwise (dis)similarities; clustering 
which is also based on pairwise similarities; partitioning schemes in which a low 
dimensional space is defined independent of the compounds themselves which are then 
mapped onto the space; and optimisation techniques such as simulated annealing and 
genetic algorithms. Recent comprehensive reviews of diversity analysis are provided by 
Gorse [9] and Maldonado et al. [10] and a review of descriptors is provided by Glen and 
Adams [11]. 
 
Random vs rational design 
 
The relative merits of random sampling versus more computationally demanding 
diversity selection has long been debated and the debate continues. For example, Yeap et 
al report the results of a simulation at Pfizer in which subsets of compounds selected at 
random from five HTS screens are compared with subsets selected using a cluster-based 
method [12]. They found that the rationally designed subsets gave higher hit rates than 
the random subsets. However, contrasting results were found by Schuffenhauer et al. in a 
recent study on Novartis datasets. Various diversity selection methods, including OptiSim 
and divisive K-means clustering, were compared with random selections over a wide 
range of assays and the diversity methods were found to be no better than random at 
selecting active compounds [13]. It was suggested that this may be due to the limited 
applicability of the similar property principle (discussed above) coupled with 
experimental errors in the screening experiment. Schuffenhauer’s study also showed that 
the OptiSim algorithm has a tendency to bias selections towards those of lower molecular 
complexity, particularly at low subset sizes, with a corresponding reduction in active 
molecules. This is thought to be due to the size bias in the Tanimoto coefficient [14] 
which favours small molecules in dissimilarity-based compound selection [3,14].   
 
Scaffold diversity 
 
A recent emphasis in diversity analysis is on scaffold, or chemotype, diversity. While 
there is no exact definition of a chemical scaffold, the term is generally used to refer to a 
common core structure that characterises a group of molecules linked by a common 
synthetic route [15].  
 
Scaffold hopping has become a popular goal in virtual screening where the aim is to 
identify active compounds that belong to different lead series from the target compound. 
Such compounds offer several advantages, for example, they may lead to new patent 
opportunities and provide alternative lead series should one fail due to poor ADME 
properties or difficult synthesis. Thus, it has become commonplace for virtual screening 
methods to be evaluated on their ability to scaffold hop rather than simply on the number 
of active compounds retrieved. This is often achieved by counting the number of unique 
molecular frameworks retrieved. The molecular framework was introduced by Bemis and 
Murko and is defined as the part of a structure that remains after all terminal acyclic 
atoms have been pruned [16]. A hierarchy of classifications can be devised by 
progressively discarding atom and bond information from the framework. A related 
approach has also been developed by Xu and Johnson called Molecular Equivalence 
Indices, MEQIs [17]. 
 
Several reviews of scaffold hopping methods and examples of scaffold hops that were 
achieved through virtual screening have appeared recently [18-20]. The interest in 
scaffold hopping has led to many new virtual screening methods which are often 
considerably more complex than the long established 2D methods involving, for 
example, 3D descriptors [21-23] and descriptors based on reduced representations of 
structures [24,25].  However, Sheridan argues that additional complexity may not always 
be necessary or even desirable, and a better approach may be to use simple descriptors 
such as atom-pairs and combine information from multiple target structures [26]. 
 
Scaffold diversity has also become a popular way of assessing and comparing databases 
of compounds and provides a different view of the data compared to methods using 
traditional descriptors such as fingerprints (See Engels et al. for a recent example of 
database comparison based on 2D fingerprints and the divisive k-means clustering 
algorithm [27].) Scaffold classification systems can be used to identify under and over 
represented scaffolds, compare scaffold coverage across different datasets and to analyse 
HTS datasets.  
 
 
Several different classification systems have been developed including the molecular 
frameworks described earlier. A limitation of these, however, is that the presence of a 
peripheral ring as a substituent may lead to a compound being classified differently to 
other compounds in the series. Thus, the HierS classification system was developed to 
group molecular frameworks hierarchically on the basis of the ring systems contained 
within them which are obtained by removing the linking bonds [28]. More recently, a 
unique hierarchical scaffold classification system has been described by Schuffenhauer et 
al. [29]. Molecular frameworks form the leaf nodes in the hierarchy with higher levels 
being obtained by iterative removal of rings. Prioritisation rules are used to ensure that 
peripheral rings are removed first so that, in contrast the HierS classification, a unique 
classification is obtained. Furthermore, each level of the hierarchy consists of well 
defined chemical substructures and should therefore be more chemically meaningful than 
the more abstract representations that are used in the framework approaches.  
 
Scaffold classification systems have been used to compare structural differences between 
drug-like and nondrug-like compounds [17], screening libraries available from 
commercial suppliers [30,31], datasets from a variety of different sources (in-house 
combinatorial library, an HTS dataset, a vendor collection and the World Drug Index) 
[28] and to analyse natural products [32]. The general aim being to identify over and 
under represented regions of scaffold space. Such comparisons have highlighted the lack 
of scaffold diversity that exists in corporate collections [2]. 
 
In a rather different approach, Fitzgerald et al. have proposed a method for comparing 
libraries based on the spatial orientations that are accessible through substitution 
positions on the library scaffolds [33]. The method is applicable to library scaffolds with 
three-points of diversity all of which are assumed to contribute to the structure-activity 
relationship. A conformational search of the scaffold is carried out (with carbon atoms at 
the substitution positions) and for each conformer, a diversity triangle is generated as the 
distances between the diversity points. A library is described by the set of diversity 
triangles generated over all conformations of the scaffold. The method has been applied 
in a recent survey of combinatorial libraries with three-points of diversity that have been 
reported in the literature since 1992 [34]. This way of describing a scaffold is similar to 
the ring system analysis described by Bohl et al. which has been applied to individual 
molecules with the aim of identifying scaffolds replacements [35]. 
 
Scaffold analysis is also being used to mine HTS data with the aim of identifying a more 
intuitive clustering than can be provided using traditional fingerprints [29,36-39].  
Scaffolds that are enriched in active compounds can be used to guide further screening 
efforts, either through database searching or through combinatorial synthesis and 
scaffolds that are close to active scaffolds in a hierarchical system may provide scaffold 
hopping opportunities. 
 
Combinatorial library design 
 
Initial efforts in combinatorial library design were aimed at diversity, however, more 
recently the emphasis has shifted to focussed designs and the design of libraries 
optimised on multiple properties simultaneously. For example, the importance of 
ensuring drug-likeness and good ADMET properties as early as possible in a project is 
well understood. Moreover, even when designing focussed libraries it is desirable to 
include an element of diversity to avoid the risk of having multiple hits coming from the 
same chemical series. Whether designing diverse or focussed libraries, the application of 
computational filters to remove compounds that have undesirable properties has become 
widespread and many such filters are available [40,41].  
 
Many approaches have been developed to design combinatorial libraries based on 
multiple properties. Often they involve the use of optimisation techniques such as genetic 
algorithms and simulated annealing.  The most common way in which multiple 
objectives are handled is to aggregate them into a single objective by, for example, using 
a weighted-sum of the individual objectives. See for example [42,43]. A more recent 
example is described by Le Bailly de Tillegham in which a desirability index is used to 
combine several properties into a single fitness value [44]. The optimisation method is 
based on a reagent exchange algorithm which starts with a random set of reagents which 
are iteratively eliminated and replaced by other reagents. 
 
However, the aggregation approach to combining objectives presents difficulties when 
the objectives are non-commensurate, for example, diversity and cost, and a trial-and-
error approach is usually taken to develop an appropriate weighting scheme. 
Furthermore, the result of combining the objectives is usually a single solution which 
represents one particular compromise in the objectives. When the objectives are in 
conflict, which is usually the case, there can be many different compromise solutions that 
are all equally valid.   
 
Evolutionary algorithms provide a convenient way to handle multiobjective optimisation 
since they are population-based and allow a family of different compromise solutions to 
be explored simultaneously. The objectives are handled independently and the concept of 
Pareto ranking is used to evolve a family of non-dominated solutions. In Pareto ranking, 
one population member is said to dominate another if it is better in one objective and at 
least as good in all others. Many different multiobjective evolutionary algorithms have 
been developed and they differ in the way in which Pareto ranking is implemented, inter 
alia. For example, in the MOGA the rank of an individual is determined by the number of 
times it is dominated so that a non-dominated individual is assigned rank 0, an individual 
dominated by one other population member is assigned rank 1, etc  [45]. In the NSGA-II 
algorithm (Non-dominated Sorting Genetic Algorithm) ranks are assigned in layers [46]. 
The dominance values of all individuals in the population are calculated and the first non-
dominated layer is identified. These individuals are then removed from the population, 
the dominance values are recalculated and the next non-dominated layer is identified and 
so on (cf with the layers of an onion). 
 
Multiobjective optimisation has been implemented in the MoSELECT program to design 
combinatorial libraries over multiple different objectives [47]. For example, it has been 
applied to the design of focussed libraries where ADME properties have been optimised 
alongside a similarity criterion [48]. The result is a family of combinatorial libraries, 
where each library represents a different trade-off in the objectives. The user is then able 
to choose a library that best suits their needs. It has also been used to explore the trade-off 
between library size (number of compounds), configuration (relative numbers of 
substituents at each position of diversity) and diversity [49]. For example, while it is 
expected that library coverage should increase with library size, a user is unlikely to 
know the exact size required for maximum coverage or when the rate of increase in 
coverage is likely to drop below some threshold. The multiobjective approach allows the 
full trade-off in size and diversity to be explored, as shown in Figure 1(a) for 
combinatorial subsets extracted from a 2-aminothiazole virtual library. It has also been 
shown that improved library designs can be achieved when a library is constructed from 
more than one combinatorial subset as shown schematically in Figure 1b (Trudi Wright, 
PhD Thesis. University of Sheffield. 2003). As the number of combinatorial subsets 
increases the number of products required to achieve maximum diversity decreases 
considerably (Figure 1c).  
 
 
Pareto optimisation has also been incorporated into commercially available library design 
software available from both Accelrys (DS Library Design, Accelrys; URL: 
http://www.accerlys.com) and Tripos [50]. For example, Soltanshahi et al. describe the 
application of OptDesign to the design of libraries focussed around known GPCR ligands 
[51]. The algorithm is based on incremental construction in which the array is built 
iteratively with a new reagent added each iteration, so that full enumeration is avoided. 
This approach allows sparse matrices to be designed as well as full combinatorial subsets. 
A small random sample of reagents is considered in each step and the one that yields the 
best set of products is chosen for inclusion in the library. The similarity of each potential 
product to the set of known actives is calculated and the reagents are ranked using Pareto 
ranking. This is in contrast to MoSELECT where entire combinatorial subsets are 
evaluated. The best reagent is then chosen based on the Pareto ranks of the products that 
are generated from it. Thus each reagent is described by a set of points in Pareto space 
with the number of points taken into consideration determined by the degree of spareness 
permitted in the final array.  
 
Multiobjective optimisation has also been applied to other applications in 
chemoinformatics as reviewed recently by Nicolaou et al. [52]  For example, Brown et al 
have developed a method for the de novo design of individual molecules (rather than 
libraries of molecules) which are optimised on similarity to a set of existing molecules 
[53]. The approach has also been extended to evolve molecules to fit quantitative-
structure property relationship (QSPR) models, such as a solubility model, with the 
inclusion of indicators of prediction accuracy [54].  
 
Pareto ranking as a tool for data analysis 
 
Pareto ranking is becoming a popular way of analysing data. For example, Figure 2 
illustrates a Pareto plot of the property profiles of compounds synthesised and tested in a 
lead optimisation project (Jeff Loo, MSc Dissertation. University of Sheffield, 2006). 
Visualisation of the entire set of compounds (shown on the left) provides a useful 
retrospective evaluation of the project, for example, the relative difficulties associated 
with optimising the different properties are readily apparent (no compounds met 
acceptable ranges for properties 4 and 9) and trade-offs in the properties can be identified 
(between properties 7 and 8 inter alia). The profile of the candidate compound is shown 
in isolation on the right, where although it did not meet the threshold for all the 
properties, it is Pareto optimal with respect to all other compounds synthesised in the 
project. This demonstrates the importance of considering multiple properties 
simultaneously since the sequential application of property filters could have led to the 
elimination of the candidate, despite it having good values for most of the properties. 
While a retrospective analysis of this type is instructive, visualisation of an optimisation 
profile during a project could provide valuable information to help guide decision 
making. The importance of achieving a balance across a range of criteria is also 
recognised by other groups [55]. 
 
Pareto ranking has also been used to analyse a number of clustering algorithms according 
to class spread (the average distance of all compounds in a class averaged over all 
clusters) and number of clusters [15]. A trade-off in these objectives exists with one 
extreme being all compounds in one cluster (minimum number of clusters; maximum 
spread) and the other extreme being each compound in its own cluster (maximum number 
of clusters; minimum spread). Many clustering methods have parameters that are used to 
control the balance in these two objectives, for example, the Kelley measure [56]. The 
Pareto analysis showed that the relative performance of different clustering algorithms 
varied depending on the region of the trade-off surface being considered. 
 
Conclusions 
 
Diversity analysis continues to be a common activity in the design of screening sets, 
especially when little is known about the target compound. A recent trend in such 
analyses has been the development of methods to assess scaffold diversity. Such 
classifications of datasets have emphasised the biases that exists in current screening 
collections and attention is now turning towards filling the gaps in scaffold space. 
Increasing scaffold coverage will not necessarily increase hit rates but may result in more 
series to progress with benefits downstream. 
 
Another area of increasing interest is the diversity available through natural products 
(NPs). Interest in NPs declined in the 1990s following the introduction of HTS 
technologies, in part due to high expectations of the new technologies and in part due to 
the difficulties associated with the isolation and synthesis of NPs. However, the poor 
performance of HTS has led to a resurgence of interest in NPs. Many comparisons have 
now been performed of NPs with drug-like compounds, and while NPs do differ from 
drugs in several properties, and therefore occupy different region of chemical space, the 
majority of them do not violate Lipinksi’s Rule-of-Five [57]. NPs therefore provide 
opportunities for exploration of new areas of chemical space relevant to biological 
activity through NP-derived libraries [32].  
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